Endpoints NewsOriginal article
Inhibrx targets OX40 agonist-cancer vaccine studies from early next year
Phase 2positivePositive
AI Analysis
Summary
Inhibrx Biosciences reports positive mid-stage data for its OX40 agonist in immunogenic cancers and plans to initiate combination studies with cancer vaccines in early 2027.
Clinical Trial Data
Phase
2
Outcome Details
Mid-stage results demonstrate potential in immunogenic cancers and in combination with cancer vaccines in lower immunogenicity tumors
Importance:5/10
Sentiment:
0.60
OX40 agonistcancer immunotherapyvaccine combinationmid-stage data
Read the original article
Published by Endpoints News on September 8, 2026 11:30 AM